Shorter DAPT Tested Following CABG - Scorecard - MDSpire

Shorter DAPT Tested Following CABG

TOP-CABG compared 3 months vs 12 months of ticagrelor plus aspirin following bypass surgery.

  • By

  • Kathryn Wighton

  • June 8, 2026

  • 6 min

Share

Clinical Scorecard: Shorter DAPT Tested Following CABG

At a Glance

CategoryDetail
Condition
Key MechanismsTicagrelor-based dual antiplatelet therapy (DAPT) for reducing SVG occlusion and bleeding risk.
Target Population
Care Setting

Key Highlights

  • Emphasize the clinical relevance of the noninferiority findings for SVG occlusion.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Monitor for SVG occlusion and bleeding events within 1 year, including specific imaging techniques.

      Risks

        Patient & Prescribing Data

        Detail patient selection criteria for the 3-month DAPT strategy.

        Clinical Best Practices

        • Include a note on excluding patients unable to tolerate early postoperative DAPT.

        Related Resources & Content

        Original Source(s)

        Shorter DAPT Tested Following CABG

        • by Kathryn Wighton

        • June 8, 2026

        Related Content

        Synthetic Echo Motion May Aid ECG Risk Modeling

        An ensemble electrocardiogram model classified derived diastolic dysfunction risk phenotypes and stratified heart failure–related death risk across external cohorts, according to findings presented at ASE 2026.

        Retatrutide Shows 28% Weight Loss in Phase 3 Trial

        Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

        FDA Approves First Oral PCSK9 Inhibitor

        Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.